Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

DNLI Denali Therapeutics Inc

23,31

0,27 (1,17%)

23 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Shares sold to cover tax obligation from settlement of vested Restricted Stock Units.

Date of Notice

01/07/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Tyler Nielsen, by power of attorney

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Denali Therapeutics Charts.

Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Denali Therapeutics Charts.

News Denali Therapeutics Inc

Form 8-K - Current report
Montag 13 Januar 2025 (1 Woche vor) • Edgar (US Regulatory)

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
Montag 13 Januar 2025 (1 Woche vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 9 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 9 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 9 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Mittwoch 8 Januar 2025 (2 Wochen vor) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Mittwoch 8 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 8 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 8 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 8 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 8 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 8 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Weitere Denali Therapeutics Inc News-Artikel

Energy Select Sector SPDR

Invesco QQQ Trust Series 1

Financial Select Sector

Deutsche Telekom

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen